Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059810 | 0.91 | LRRK2 (0.65) | LRRK2EGFRPRKDCLATS1AAK1 | |
| SCHEMBL17135925 | 0.91 | LRRK2 (0.65) | LRRK2EGFRPRKDCLATS1AAK1 | |
| SCHEMBL14059811 | 0.91 | LRRK2 (0.65) | LRRK2EGFRPRKDCLATS1AAK1 | |
| SCHEMBL14059965 | 0.84 | LRRK2 (0.71) | LRRK2 | |
| SCHEMBL14059542 | 0.82 | LRRK2 (0.64) | LRRK2 | |
| SCHEMBL17135911 | 0.80 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL14059734 | 0.78 | LRRK2 (0.63) | LRRK2LATS1AAK1 | |
| SCHEMBL17135956 | 0.78 | LRRK2 (0.74) | LRRK2 | |
| SCHEMBL17135957 | 0.78 | LRRK2 (0.74) | LRRK2 | |
| SCHEMBL14062231 | 0.77 | LRRK2 (0.77) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | claimed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | claimed |
| CN-103917525-A | Inhibitors of LRRK2 kinase activity | ELAN PHARM INC | 2014-07-09 | — | — | CN | claimed |
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| CN-103917525-B | The inhibitor of LRRK2 kinase activity | 依兰制药公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| CN-103917525-A | Inhibitors of LRRK2 kinase activity | ELAN PHARM INC | 2014-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | LRRK2, PARK7, PINK1 | LRRK2 1/4885KDM4E 1167/4885EGFR 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.